Truist Securities Maintains Buy on Axsome Therapeutics, Maintains $150 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Joon Lee has maintained a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) with a price target of $150.
March 26, 2024 | 1:23 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities maintains a Buy rating on Axsome Therapeutics with a $150 price target.
The maintenance of a Buy rating and a high price target by a reputable analyst like Joon Lee from Truist Securities is likely to instill confidence among investors and could lead to a positive short-term impact on AXSM's stock price. The reaffirmation of the $150 price target suggests a strong belief in the company's future performance and growth potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100